# Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2023 > Briefs, arguments, decisions, and more. URL: https://www.frixlaw.com/law-library/documents/fr%3A2023-23931 ## Record - **Collection:** Federal Register - **Document type:** Notice - **Published:** October 31, 2023 - **Citation:** 88 FR 74512 ## Text DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA-1051A] Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2023 AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Notice with request for comments. SUMMARY: The Drug Enforcement Administration (DEA) proposes to adjust the 2023 aggregate production quotas for several controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemical phenylpropanolamine. DATES: Interested persons may file written comments on this notice in accordance with 21 CFR 1303.13(c) and 1315.13(d). Electronic comments must be submitted, and written comments must be postmarked, on or before November 30, 2023. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period. Based on comments received in response to this notice, the Administrator may hold a public hearing on one or more issues raised. In the event the Administrator decides in her sole discretion to hold such a hearing, the Administrator will publish a notice of any such hearing in the Federal Register . After consideration of any comments or objections, or after a hearing, if one is held, the Administrator will publish in the Federal Register a final order establishing the 2023 adjusted aggregate production quotas for schedule I and II controlled substances, and an adjusted assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, as relevant. ADDRESSES: To ensure proper handling of comments, please reference “Docket No. DEA-1051A” on all correspondence, including any attachments. DEA encourages that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to http://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon completion of your submission, you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on Regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. Paper comments that duplicate electronic submissions are not necessary and are discouraged. Should you wish to mail a paper comment in lieu of an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. FOR FURTHER INFORMATION CONTACT: Scott A. Brinks, Regulatory Drafting and Policy Support Section, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152, Telephone: 571-776-3882. SUPPLEMENTARY INFORMATION: Posting of Public Comments Please note that all comments received in response to this docket are considered part of the public record. The Drug Enforcement Administration (DEA) will make comments available for public inspection online at http://www.regulations.gov. Such information includes personal or business identifiers (such as name, address, state or Federal identifiers, etc.) voluntarily submitted by the commenter. Generally, all information voluntarily submitted by the commenter, unless clearly marked as Confidential Information in the method described below, will be publicly posted. Comments may be submitted anonymously. The Freedom of Information Act applies to all comments received. Commenters submitting comments which include personal identifying information (PII), confidential, or proprietary business information that the commenter does not want made publicly available should submit two copies of the comment. One copy must be marked “CONTAINS CONFIDENTIAL INFORMATION” and should clearly identify all PII or business information the commenter does not want to be made publicly available, including any supplemental materials. DEA will review this copy, including the claimed PII and confidential business information, in its consideration of comments. The second copy should be marked “TO BE PUBLICLY POSTED” and must have all claimed confidential PII and business information already redacted. DEA will post only the redacted comment on http://www.regulations.gov for public inspection. For easy reference, an electronic copy of this document is available at http://www.regulations.gov. Legal Authority and Background Section 306 of the CSA (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas (APQ) for each basic class of controlled substance listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of DEA. 1 1 28 CFR 0.100(b). DEA established the 2023 APQ for substances in schedules I and II and the assessment of annual needs (AAN) for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine on December 2, 2022. 2 That order stipulated that, in accordance with 21 CFR 1303.13 and 1315.13, all APQ and AAN are subject to adjustment. 2 Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2023, 87 FR 74168 (December 2, 2022). Analysis for Proposed Adjusted 2023 Aggregate Production Quotas and Assessment of Annual Needs DEA proposes to adjust the established 2023 APQ for certain schedule I and II controlled substances and the AAN for certain list I chemicals to be manufactured in the United States (U.S.) in 2023 to provide for the estimated medical, scientific, research, and industrial needs of the U.S., for lawful export requirements, and for the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes. Factors for Determining the Proposed Adjustments In determining the proposed adjustments, the Administrator has taken into account the factors in 21 CFR 1303.13 (adjustment of APQ for controlled substances) and 21 CFR 1315.13 (adjustment of the AAN for ephedrine, pseudoephedrine, and phenylpropanolamine). The Administrator is authorized to increase or reduce the APQ and the AAN at any time. 3 3 21 CFR 1303.13(a) and 1315.13(a). DEA determined whether to propose an adjustment of the APQ for 2023 by considering the factors found at 21 CFR 1303.13(b): 4 4 DEA recently adopted revisions to its regulations for setting quotas, but that rule has not yet taken effect and does not affect this notice proposing some adjustments to the 2023 APQs. Management of Quotas for Controlled Substances and List I Chemicals, 88 FR 60117 (Aug. 31, 2023) (effective Nov. 29, 2023). (1) Changes in the demand for that class, changes in the national rate of net disposal of the class, changes in the rate of net disposal of the class by registrants holding individual manufacturing quotas for that class, and changes in the extent of any diversion in the class; (2) Whether any increased demand for that class, the national and/or individual rates of net disposal of that class are temporary, short term, or long term; (3) Whether any increased demand for that class can be met through existing inventories, increased individual manufacturing quotas, or increased importation, without increasing the aggregate production quota, taking into account production delays and the probability that other individual manufacturing quotas may be suspended pursuant to Sec. 1303.24(b); (4) Whether any decreased demand for that class will result in excessive inventory accumulation by all persons registered to handle that class (including manufacturers, distributors, practitioners, importers, and exporters), notwithstanding the possibility that individual manufacturing quotas may be suspended pursuant to Sec. 1303.24(b) or abandoned pursuant to Sec. 1303.27; (5) Other factors affecting medical, scientific, research, and industrial needs in the United States and lawful export requirements, as the Administrator finds relevant, including changes in the currently accepted medical use in treatment with the class or the substances which are manufactured from it, the economic and physical availability of raw materials for use in manufacturing and for inventory purposes, yield and stability problems, potential disruptions to production (including possible labor strikes), and recent unforeseen emergencies such as floods and fires. DEA also considered updated information obtained from 2022 year-end inventories, 2022 disposition data submitted by quota applicants, changes in estimates of the medical needs of the U.S., export requirements, and other information made available to DEA after the initial APQ and AAN had been established. Additional factors the Administrator considered in calculating the APQ, but not the AAN, include product development requirements of both bulk and finished dosage form manufacturers. After considering the changes in the extent of diversion of all controlled substances, as required by 21 CFR 1303.13(b)(1), DEA has determined that any changes from the initial calculations are slight and not statistically significant from the estimates of diversion that DEA applied to the initial APQ valuations. DEA determined whether to propose an adjustment of the AAN for 2023 by considering the factors found at 21 CFR 1315.13(b) and summarized below: (1) Changes in the demand for that chemical, changes in the national rate of net disposal of the chemical, and changes in the rate of net disposal of the chemical by registrants holding individual manufacturing or import quotas for that chemical; (2) Whether any increased demand for that chemical, the national and/or changes in individual rates of net disposal of that chemical are temporary, short term, or long term; (3) Whether any increased demand for that chemical can be met through existing inventories, increased individual manufacturing quotas, or increased importation, without increasing the assessment of annual needs, taking into account production delays and the probability that other individual manufacturing quotas may be suspended pursuant to Sec. 1315.24(b); (4) Whether any decreased demand for that chemical will result in excessive inventory accumulation by all persons registered to handle that chemical (including manufacturers, distributors, importers, and exporters), notwithstanding the possibility that individual manufacturing quotas may be suspended pursuant to Sec. 1315.24(b) or abandoned pursuant to Sec. 1315.27; (5) Other factors affecting medical, scientific, research, industrial, and importation needs in the United States, lawful export requirements, and reserve stocks, as the Administrator finds relevant, including changes in the currently accepted medical use in treatment with the chemical or the substances that are manufactured from it, the economic and physical availability of raw materials for use in manufacturing and for inventory purposes, yield and stability problems, potential disruptions to production (including possible labor strikes), and recent unforeseen emergencies such as floods and fires. In evaluating whether there is a need for adjustment of the 2023 AAN for list I chemicals, DEA used the calculation methodology previously described in the 2010 and 2011 assessment of annual needs. 5 DEA considered the total net disposals of the list I chemicals for the current and preceding two years, actual and estimated inventories, projected demand, industrial use, and export requirements from data provided by DEA registered manufacturers and importers on the relevant quota application forms. 6 5 74 FR 60294 (Nov. 20, 2009) and 75 FR 79407 (Dec. 20, 2010). 6 Id. Additional Considerations Applicable to Covered Controlled Substances When setting APQ, the Administrator must estimate the amount of diversion of any substance that is considered a “covered controlled substance.” 7 The covered controlled substances are fentanyl, oxycodone, hydrocodone, oxymorphone, and hydromorphone. 8 DEA is required to “make appropriate quota reductions, as determined by the [Administrator], from the quota the [Administrator] would have otherwise established had such diversion not been considered.” 9 When estimating diversion, the Administrator “shall consider information,” in consultation with the Secretary of Health and Human Services, the Administrator “determines reliable on rates of overdose deaths and abuse and overall public health impact related to the covered controlled substance in the United States;” and “may take into consideration” whatever other sources of information they determine reliable. 10 7 21 U.S.C. 826(i)(1)(A). 8 21 U.S.C. 826(i)(1)(A). 9 All functions vested in the Attorney General by the CSA have been delegated to the Administrator of DEA. 28 CFR 0.100(b); 21 U.S.C. 826(i)(1)(C). 10 21 U.S.C. 826(i)(1)(B). DEA sent letters to the Centers for Disease Control and Prevention (CDC), and the states in February, April, and May 2023 requesting overdose death and overprescribing data that could be considered in estimating diversion. DEA received information from the CDC in April 2023 and received Prescription Data Monitoring Program (PDMP) data from the states in May and June 2023. DEA considered this information in developing the estimates of diversion for the five covered controlled substances for this proposed adjustment. To determine the estimates of diversion, DEA also aggregated data for each covered controlled substance from the Drug Theft and Loss Reports. DEA gathered data involving employee theft, break-ins, armed robberies, and material lost in transit. DEA calculated the metric weight in grams of each active pharmaceutical ingredient (API) of the controlled substances being diverted as identified in these reports. In calculating the estimates of diversion, DEA utilized the same methodology as published in the Proposed APQ for Schedule I and II Controlled Substances and AAN for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2023. 11 Below, DEA provides an updated chart showing estimations of diversion for each of the covered controlled substances. 11 87 FR 63091 (October 18, 2022). Diversion Estimates for 2023 ( g ) Fentanyl 59 Hydrocodone 133,004 Hydromorphone 595 Oxycodone 174,797 Oxymorphone 109 Proposed Adjustments for the 2023 Aggregate Production Quotas and Assessment of Annual Needs DEA is proposing increases to the APQ for the following schedule I substances: all other tetrahydrocannabinol, delta-9-tetrahydrocannabinol, ibogaine, psilocybin, and psilocyn. These proposed increases are to support research and clinical trials by DEA-registered schedule I researchers. These proposed increases demonstrate DEA's support for research with schedule I controlled substances. DEA established the 2023 APQs for substances in schedules I and II on December 2, 2022. 12 Subsequent to that publication, DEA published in the Federal Register final rules to permanently schedule four synthetic drugs under the CSA. 13 The specific synthetic substances are eutylone, mesocarb, methiopropamine, and zipeprol. As a result, these substances will continue to be subject to the CSA schedule I controls and DEA is proposing to assign individual APQ for each substance pursuant to 21 U.S.C. 826 and 21 CFR part 1303. 12 87 FR 74168. 13 87 FR 70717 (November 21, 2022), 87 FR 71247 (November 22, 2022), 87 FR 20318 (April, 7 2022), and 87 FR 32996 (June 1, 2022). DEA previously adjusted the established 2023 aggregate production quota for the schedule II-controlled substance methylphenidate (for sale) to be manufactured in the United States to provide for the estimated needs of the United States and export requirements in accordance with 21 U.S.C. 826(h). 14 This adjustment was necessary to ensure that the United States has an adequate and uninterrupted supply of methylphenidate (for sale) to meet legitimate patient needs both domestically and globally. 14 Adjustment to the Aggregate Production Quota for Methylphenidate (for Sale) for 2023, 88 FR 68147 (October 3, 2023). The Administrator, therefore, proposes to adjust the 2023 APQ for the schedule I controlled substances of all other tetrahydrocannabinol, delta-9-tetrahydrocannabinol, eutylone, ibogaine, mesocarb, methiopropamine, psilocybin, psilocyn, and zipeprol. The proposed adjusted APQ and AAN, as expressed in grams of anhydrous acid or base, are as follows: Basic class Established 2023 quotas (g) Proposed revised 2023 quotas (g) Schedule I 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 20 no change. 1-(1-Phenylcyclohexyl)pyrrolidine 30 no change. 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 10 no change. 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) 30 no change. 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) 30 no change. 1-[1-(2-Thienyl)cyclohexyl]piperidine 15 no change. 2′-fluoro 2-fluorofentanyl 30 no change. 1-Benzylpiperazine 25 no change. 1-Methyl-4-phenyl-4-propionoxypiperidine 10 no change. 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) 30 no change. 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) 30 no change. 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) 30 no change. 2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) 30 no change. 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) 100 no change. 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) 30 no change. 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) 30 no change. 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) 25 no change. 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) 30 no change. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) 30 no change. 2,5-Dimethoxy-4-ethylamphetamine (DOET) 25 no change. 2,5-Dimethoxy-4-n-propylthiophenethylamine 25 no change. 2,5-Dimethoxyamphetamine 25 no change. 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) 30 no change. 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) 30 no change. 3,4,5-Trimethoxyamphetamine 30 no change. 3,4-Methylenedioxyamphetamine (MDA) 12,000 no change. 3,4-Methylenedioxymethamphetamine (MDMA) 12,000 no change. 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) 40 no change. 3,4-Methylenedioxy-N-methylcathinone (methylone) 5,200 no change. 3,4-Methylenedioxypyrovalerone (MDPV) 35 no change. 3-FMC; 3-Fluoro-N-methylcathinone 25 no change. 3-Methylfentanyl 30 no change. 3-Methylthiofentanyl 30 no change. 4-Bromo-2,5-dimethoxyamphetamine (DOB) 5,100 no change. 4-Bromo-2,5-dimethoxyphenethylamine (2-CB) 25 no change. 4-Chloro- alpha -pyrrolidinovalerophenone (4-chloro- alpha -PVP) 25 no change. 4-CN-Cumyl-Butinaca 25 no change. 4,4′-Dimethylaminorex 30 no change. 4-Fluoroisobutyryl fentanyl 30 no change. 4F-MDMB-BINACA 30 no change. 4-FMC; Flephedrone 25 no change. 4-MEC; 4-Methyl-N-ethylcathinone 25 no change. 4-Methoxyamphetamine 150 no change. 4-Methyl-2,5-dimethoxyamphetamine (DOM) 25 no change. 4-Methylaminorex 25 no change. 4-Methyl-N-methylcathinone (mephedrone) 45 no change. 4-Methyl- alpha -ethylaminopentiophenone (4-MEAP) 25 no change. 4-Methyl- alpha -pyrrolidinohexiophenone (MPHP) 25 no change. 4′-Methyl acetyl fentanyl 30 no change. 4-Methyl-α-pyrrolidinopropiophenone (4-MePPP) 25 no change. 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol 50 no change. 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) 40 no change. 5F-AB-PINACA; (1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 25 no change. 5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) 25 no change. 5F-CUMYL-P7AICA; 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3carboximide 25 no change. 5F-CUMYL-PINACA 25 no change. 5F-EDMB-PINACA 25 no change. 5F-MDMB-PICA 25 no change. 5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) 25 no change. 5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) 25 no change. 5-Fluoro-PB-22; 5F-PB-22 25 no change. 5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone 25 no change. 5-Methoxy-3,4-methylenedioxyamphetamine 25 no change. 5-Methoxy-N,N-diisopropyltryptamine 25 no change. 5-Methoxy-N,N-dimethyltryptamine 11,000 no change. AB-CHMINACA 30 no change. AB-FUBINACA 50 no change. AB-PINACA 30 no change. ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) 30 no change. Acetorphine 25 no change. Acetyl Fentanyl 100 no change. Acetyl- alpha -methylfentanyl 30 no change. Acetyldihydrocodeine 30 no change. Acetylmethadol 25 no change. Acryl Fentanyl 25 no change. ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) 50 no change. AH-7921 30 no change. All other tetrahydrocannabinol 15,000 350,000. Allylprodine 25 no change. Alphacetylmethadol 25 no change. alpha -Ethyltryptamine 25 no change. Alphameprodine 25 no change. Alphamethadol 25 no change. alpha -Methylfentanyl 30 no change. alpha -Methylthiofentanyl 30 no change. alpha -Methyltryptamine (AMT) 25 no change. alpha -Pyrrolidinobutiophenone (α-PBP) 25 no change. alpha -pyrrolidinoheptaphenone (PV8) 25 no change. alpha -pyrrolidinohexabophenone (α -PHP) 25 no change. alpha -Pyrrolidinopentiophenone (α-PVP) 25 no change. Amineptine 30 no change. Aminorex 25 no change. Anileridine 20 no change. APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) 25 no change. Benzethidine 25 no change. Benzylmorphine 30 no change. Betacetylmethadol 25 no change. beta -Hydroxy-3-methylfentanyl 30 no change. beta -Hydroxyfentanyl 30 no change. beta -Hydroxythiofentanyl 30 no change. beta -Methyl fentanyl 30 no change. beta -Phenyl fentanyl 30 no change. Betameprodine 25 no change. Betamethadol 4 no change. Betaprodine 25 no change. Brorphine 30 no change. Bufotenine 15 no change. Butonitazene 30 no change. Butylone 25 no change. Butyryl fentanyl 30 no change. Cathinone 40 no change. Clonitazene 25 no change. Codeine methylbromide 30 no change. Codeine-N-oxide 192 no change. Crotonyl Fentanyl 25 no change. Cyclopentyl Fentanyl 30 no change. Cyclopropyl Fentanyl 20 no change. Cyprenorphine 25 no change. d-9-THC 384,460 628,460. Desomorphine 25 no change. Dextromoramide 25 no change. Diapromide 20 no change. Diethylthiambutene 20 no change. Diethyltryptamine 25 no change. Difenoxin 9,300 no change. Dihydromorphine 653,548 no change. Dimenoxadol 25 no change. Dimepheptanol 25 no change. Dimethylthiambutene 20 no change. Dimethyltryptamine 3,000 no change. Dioxyaphetyl butyrate 25 no change. Dipipanone 25 no change. Drotebanol 25 no change. Ethylmethylthiambutene 25 no change. Ethylone 25 no change. Etonitazene 25 no change. Etodesnitazene 30 no change. Etorphine 30 no change. Etoxeridine 25 no change. Eutylone N/A 30. Fenethylline 30 no change. Fentanyl carbamate 30 no change. Fentanyl related substances 600 no change. FUB-144 25 no change. Flunitazene 30 no change. FUB-AKB48 25 no change. Fub-AMB, MMB-Fubinaca, AMB-Fubinaca 25 no change. Furanyl fentanyl 30 no change. Furethidine 25 no change. gamma -Hydroxybutyric acid 29,417,000 no change. Heroin 150 no change. Hydromorphinol 40 no change. Hydroxypethidine 25 no change. Ibogaine 30 150. Isobutyryl Fentanyl 25 no change. Isotonitazine 25 no change. JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) 35 no change. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) 45 no change. JWH-073 (1-Butyl-3-(1-naphthoyl)indole) 45 no change. JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) 30 no change. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) 30 no change. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) 35 no change. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) 30 no change. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) 30 no change. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) 30 no change. Ketobemidone 30 no change. Levomoramide 25 no change. Levophenyacylmorphan 25 no change. Lysergic acid diethylamide (LSD) 1,200 no change. MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) 30 no change. MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) 30 no change. MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) 30 no change. MMB-CHMICA-(AMB-CHIMCA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate 25 no change. Marijuana 6,675,000 no change. Marijuana extract 1,000,000 no change. Mecloqualone 30 no change. Mescaline 1,200 no change. Mesocarb N/A 30. Methaqualone 60 no change. Methcathinone 25 no change. Methiopropamine N/A 30. Methoxetamine 30 no change. Methoxyacetyl fentanyl 30 no change. Methyldesorphine 5 no change. Methyldihydromorphine 25 no change. Metodesnitazene 30 no change. Metonitazene 30 no change. Morpheridine 25 no change. Morphine methylbromide 5 no change. Morphine methylsulfonate 5 no change. Morphine-N-oxide 150 no change. MT-45 30 no change. Myrophine 25 no change. NM2201: Naphthalen-1-yl 1-(5-fluorpentyl)-1H-indole-3-carboxylate 25 no change. N,N-Dimethylamphetamine 25 no change. Naphyrone 25 no change. N-Ethyl-1-phenylcyclohexylamine 25 no change. N-Ethyl-3-piperidyl benzilate 10 no change. N-Ethylamphetamine 24 no change. N-Ethylhexedrone 25 no change. N-Ethylpentylone, ephylone 30 no change. N-Hydroxy-3,4-methylenedioxyamphetamine 24 no change. Nicocodeine 25 no change. Nicomorphine 25 no change. N-methyl-3-piperidyl benzilate 30 no change. Noracymethadol 25 no change. N-Pyrrolidino Etonitazene 30 no change. Norlevorphanol 2,550 no change. Normethadone 25 no change. Normorphine 40 no change. Norpipanone 25 no change. Ocfentanil 25 no change. ortho -Fluoroacryl fentanyl 30 no change. ortho -Fluorobutyryl fentanyl 30 no change. ortho -Fluorofentanyl,2-Fluorofentanyl 30 no change. ortho -Fluoroisobutyryl fentanyl 30 no change. ortho -Methyl acetylfentanyl 30 no change. ortho -Methyl methoxyacetyl fentanyl 30 no change. Para -Chlorisobutyrl fentanyl 30 no change. Para -flourobutyryl fentanyl 25 no change. Para -fluorofentanyl 25 no change. Para -Fluoro furanyl fentanyl 30 no change. Para -Methoxybutyrl fentanyl 30 no change. Para -methoxymethamphetamine 30 no change. Para -Methylfentanyl 30 no change. Parahexyl 5 no change. PB-22; QUPIC 20 no change. Pentedrone 25 no change. Pentylone 25 no change. Phenadoxone 25 no change. Phenampromide 25 no change. Phenomorphan 25 no change. Phenoperidine 25 no change. Phenyl fentanyl 30 no change. Pholcodine 5 no change. Piritramide 25 no change. Proheptazine 25 no change. Properidine 25 no change. Propiram 25 no change. Protonitazene 30 no change. Psilocybin 8,000 15,000. Psilocyn 12,000 24,000. Racemoramide 25 no change. SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) 45 no change. SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) 30 no change. Tetrahydrofuranyl fentanyl 15 no change. Thebacon 25 no change. Thiafentanil 25 no change. Thiofentanyl 25 no change. Thiofuranyl fentanyl 30 no change. THJ-2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) 30 no change. Tilidine 25 no change. Trimeperidine 25 no change. UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 25 no change. U-47700 30 no change. Valeryl fentanyl 25 no change. Zipeprol N/A 30. Schedule II 1-Phenylcyclohexylamine 15 no change. 1-Piperidinocyclohexanecarbonitrile 25 no change. 4-Anilino-N-phenethyl-4-piperidine (ANPP) 937,874 no change. Alfentanil 5,000 no change. Alphaprodine 25 no change. Amobarbital 20,100 no change. Amphetamine (for sale)(split) N/A no change. Bezitramide 25 no change. Carfentanil 20 no change. Cocaine 60,492 no change. Codeine (for conversion) 1,085,024 no change. Codeine (for sale) 21,003,397 no change. D-amphetamine (for sale) 21,200,000 no change. D,l-amphetamine 21,200,000 no change. D-amphetamine (for conversion) 20,000,000 no change. Dexmethylphenidate (for sale) 6,200,000 no change. Dexmethylphenidate (for conversion) 4,200,000 no change. Dextropropoxyphene 35 no change. Dihydrocodeine 132,658 no change. Dihydroetorphine 25 no change. Diphenoxylate (for conversion) 14,100 no change. Diphenoxylate (for sale) 770,800 no change. Ecgonine 60,492 no change. Ethylmorphine 30 no change. Etorphine hydrochloride 32 no change. Fentanyl 731,452 no change. Glutethimide 25 no change. Hydrocodone (for conversion) 1,250 no change. Hydrocodone (for sale) 27,239,822 no change. Hydromorphone 1,994,125 no change. Isomethadone 30 no change. L-amphetamine 30 no change. Levo-alphacetylmethadol (LAAM) 25 no change. Levomethorphan 30 no change. Levorphanol 23,010 no change. Lisdexamfetamine 26,500,000 no change. Meperidine 681,289 no change. Meperidine Intermediate-A 30 no change. Meperidine Intermediate-B 30 no change. Meperidine Intermediate-C 30 no change. Metazocine 15 no change. Methadone (for sale) 25,619,700 no change. Methadone Intermediate 27,673,600 no change. Methamphetamine 150 no change. d-methamphetamine (for conversion) 485,020 no change. d-methamphetamine (for sale) 47,000 no change. l-methamphetamine 587,229 no change. Methylphenidate (for sale) 53,283,000 no change. Methylphenidate (for conversion) 15,300,000 no change. Metopon 25 no change. Moramide-intermediate 25 no change. Morphine (for conversion) 2,458,460 no change. Morphine (for sale) 21,747,625 no change. Nabilone 62,000 no change. Norfentanyl 25 no change. Noroxymorphone (for conversion) 22,044,741 no change. Noroxymorphone (for sale) 1,000 no change. Oliceridine 25,100 no change. Opium (powder) 250,000 no change. Opium (tincture) 530,837 no change. Oripavine 33,010,750 no change. Oxycodone (for conversion) 437,827 no change. Oxycodone (for sale) 53,840,608 no change. Oxymorphone (for conversion) 28,204,371 no change. Oxymorphone (for sale) 516,351 no change. Pentobarbital 33,843,337 no change. Phenazocine 25 no change. Phencyclidine 35 no change. Phenmetrazine 25 no change. Phenylacetone 100 no change. Piminodine 25 no change. Racemethorphan 5 no change. Racemorphan 5 no change. Remifentanil 3,000 no change. Secobarbital 172,100 no change. Sufentanil 4,000 no change. Tapentadol 11,941,416 no change. Thebaine 57,137,944 no change. List I Chemicals Ephedrine (for conversion) 41,100 no change. Ephedrine (for sale) 4,136,000 no change. Phenylpropanolamine (for conversion) 14,878,320 no change. Phenylpropanolamine (for sale) 7,990,000 no change. Pseudoephedrine (for conversion) 1,000 no change. Pseudoephedrine (for sale) 174,246,000 no change. The Administrator further proposes that APQ for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. In accordance with 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Administrator may adjust the 2023 APQ and AAN as needed. Conclusion After consideration of any comments or objections, or after a hearing, if one is held, the Administrator will issue and publish in the Federal Register a final order establishing any adjustment of the 2023 APQ for each basic class of controlled substances in schedules I and II and AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. 15 15 21 CFR 1303.13(c) and 1315.13(c). Signing Authority This document of the Drug Enforcement Administration was signed on October 25, 2023, by Administrator Anne Milgram. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the Federal Register . Scott Brinks, Federal Register Liaison Officer, Drug Enforcement Administration. [FR Doc. 2023-23931 Filed 10-30-23; 8:45 am] BILLING CODE P --- Source: Frix Law Library, https://www.frixlaw.com/law-library/documents/fr%3A2023-23931. Public record. Not legal advice.